"Pro Medicus's five new contracts should underpin accelerating revenue growth into the imaging-tech provider's 2025 fiscal year, Goldman Sachs analysts tell clients in a note. They still anticipate 27% growth in fiscal 2024 revenue, but they lift their forecast for fiscal 2025 revenue growth to 32% from 30%. The GS analysts observe that the announced contract sizes contain no direct component from either AI or cardiology, which they suspect points to further potential upside over the medium term. GS raises its target price 1.5%, to A$136.00, and keeps a "buy" rating on the stock, which is at A$114.31 ahead of the open."
Ann: PME signs five new deals with a combined minimum of A$45M, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$314.20 |
Change
4.220(1.36%) |
Mkt cap ! $32.82B | |||
| Open | High | Low | Value | Volume |
| $312.00 | $315.66 | $309.65 | $53.80M | 171.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 758 | $313.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $314.20 | 59 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2025 (20 minute delay) ? |
| PME (ASX) Chart |